Orally Administered, Biodegradable and Biocompatible Hydroxypropyl-β-Cyclodextrin Grafted Poly(methacrylic acid) Hydrogel for pH Sensitive Sustained Anticancer Drug Delivery.
colorectal cancer
cytarabine
half-life
hydroxypropyl–β–cyclodextrin
pharmacokinetics
Journal
Gels (Basel, Switzerland)
ISSN: 2310-2861
Titre abrégé: Gels
Pays: Switzerland
ID NLM: 101696925
Informations de publication
Date de publication:
19 Mar 2022
19 Mar 2022
Historique:
received:
22
02
2022
revised:
16
03
2022
accepted:
17
03
2022
entrez:
24
3
2022
pubmed:
25
3
2022
medline:
25
3
2022
Statut:
epublish
Résumé
In the current study, a pH sensitive intelligent hydroxypropyl-β-cyclodextrin-based polymeric network (HP-β-CD-g-MAA) was developed through a solution polymerization technique for site specific delivery of cytarabine in the colonic region. Prepared hydrogel formulations were characterized through cytarabine loading (%), ingredient's compatibility, structural evaluation, thermal integrity, swelling pattern, release behavior and toxicological profiling in rabbits. Moreover, the pharmacokinetic profile of cytarabine was also determined in rabbits. New polymer formation was evident from FTIR findings. The percentage loaded into the hydrogels was in the range of 37.17-79.3%. Optimum swelling ratio of 44.56 was obtained at pH 7.4. Cytarabine release was persistent and in a controlled manner up to 24 h. In vitro degradation of hydrogels was more pronounced at intestinal pH as compared to acidic pH. Toxicity studies proved absence of any ocular, skin and oral toxicity, thus proving biocompatibility of the fabricated network. Hydrogels exhibited longer plasma half-life (8.75 h) and AUC (45.35 μg.h/mL) with respect to oral cytarabine solution. Thus, the developed hydrogel networks proved to be excellent and biocompatible cargo for prolonged and site-specific delivery of cytarabine in the management of colon cancer.
Identifiants
pubmed: 35323303
pii: gels8030190
doi: 10.3390/gels8030190
pmc: PMC8953841
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Oncol. 2018 Apr 1;29(4):973-978
pubmed: 29390048
Saudi Pharm J. 2016 Sep;24(5):554-559
pubmed: 27752227
Int J Biol Macromol. 2022 Mar 31;202:332-344
pubmed: 35041883
Int J Pharm. 2016 Sep 10;511(1):161-169
pubmed: 27377011
3 Biotech. 2018 Dec;8(12):493
pubmed: 30498666
Int J Biol Macromol. 2018 Apr 15;110:167-178
pubmed: 29462679
Biomaterials. 2001 May;22(10):1077-84
pubmed: 11352088
Daru. 2013 May 30;21(1):44
pubmed: 23721569
Int J Pharm. 2014 Oct 1;473(1-2):560-71
pubmed: 25066076
Nanomaterials (Basel). 2020 Jun 12;10(6):
pubmed: 32545473
Drug Deliv. 2004 Jan-Feb;11(1):53-8
pubmed: 15168792
J Adv Res. 2015 Mar;6(2):105-21
pubmed: 25750745
Drug Deliv Transl Res. 2019 Apr;9(2):555-577
pubmed: 29450805
Drug Deliv. 2018 Nov;25(1):916-927
pubmed: 29649903
J Adv Res. 2018 Jun 25;15:1-18
pubmed: 30581608
Nat Rev Drug Discov. 2004 Dec;3(12):1023-35
pubmed: 15573101
Biomed Res Int. 2013;2013:239838
pubmed: 24364030
J Pharm Bioallied Sci. 2010 Apr;2(2):72-9
pubmed: 21814436
Nanomaterials (Basel). 2019 Jan 20;9(1):
pubmed: 30669533
Expert Opin Drug Deliv. 2014 Jun;11(6):901-15
pubmed: 24848309